AARD INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026

Faruqi & Faruqi is investigating potential securities-law claims against Aardvark Therapeutics (NASDAQ: AARD) and highlighted an October 13, 2026 deadline for investors to seek lead-plaintiff status in a federal class action. The suit covers Aardvark shares acquired in or traceable to its February 13, 2025 IPO, as well as securities purchased from February 13, 2025 through May 14, 2026, creating litigation and reputational risk for the company.

Analysis

The lead-plaintiff deadline is principally a technical-flow event, not an assessment of merits. For AARD, the more relevant valuation question is whether alleged disclosure gaps affect the probability-adjusted value of its clinical pipeline, financing runway, or commercial assumptions; absent a revised regulatory, clinical, or cash-burn datapoint, litigation alone rarely changes biotech intrinsic value. Near-term, however, a thinly traded post-IPO biotech can see incremental selling from holders constrained by governance or litigation screens, while short interest may rise into any related filing or company response.

The second-order risk is capital formation. AARD's ability to fund development depends on maintaining access to follow-on equity, ATM capacity, or partnership capital; a depressed share price raises dilution required for each dollar of runway and can compress negotiating leverage with strategic partners. This becomes material over the next 6-18 months only if cash runway is limited relative to upcoming trial or regulatory milestones. Comparable small-cap biotech litigation headlines generally create an opportunity only when the stock selloff materially exceeds the expected dilution and legal-cost impact.

Contrarian view: the market may over-attribute legal headlines to fundamental impairment. Plaintiffs' firms commonly publicize deadlines, and the deadline itself neither establishes liability nor forces a settlement. AARD becomes actionable on the long side only if the stock declines on litigation flow while management reaffirms cash runway and the next value-inflecting clinical/regulatory catalyst remains intact; otherwise, the appropriate stance is to avoid initiating exposure until the underlying alleged facts and balance-sheet sensitivity are independently verified.

Key Decisions for Investors

• No standalone directional trade on the October 13 deadline; treat it as a liquidity/volatility alert rather than a fundamental catalyst.
• Monitor AARD for a 1-3 month dislocation: consider a small long only after verifying cash runway, trial timelines, and that no guidance or regulatory revision accompanies the litigation. Size for binary biotech risk; invalidate on a financing announcement materially below prevailing market price or a program-delay disclosure.
• For existing AARD longs, reduce gross exposure ahead of any company response or new complaint details if position size assumes uninterrupted capital access; use any litigation-driven rebound to rebalance until dilution risk is quantified.
• Watch peer small-cap biotech financing terms rather than broad biotech ETFs: a weak follow-on market would amplify AARD's cost-of-capital risk over 6-18 months, whereas a strategic partnership or non-dilutive funding announcement would directly falsify the bearish financing thesis.